Tipsheet
What matters at India’s listed companies
Earnings · Pharmaceuticals · Small cap

NGL Fine-Chem profit jumps 128% as India revenue more than doubles

Consolidated net profit surged to ₹48.13 crore in FY26, outpacing a 36% rise in revenue to ₹500.95 crore on broad-based demand.

4 earlier stories on NGL Fine-Chem Ltd.
Mkt cap₹1,847 cr
P/E38.38×
ROE7.39%
Debt / eq.0.27
Div yld0.06%
₹48.13 cr FY26 consolidated net profit, up 128% year-on-year.

What's new

  • NGL Fine-Chem's FY26 consolidated revenue rose 36% to ₹500.95 crore; net profit jumped 128% to ₹48.13 crore.
  • India revenue more than doubled to ₹157.90 crore; rest-of-world jumped 78% to ₹190.94 crore.
  • Board recommended a final dividend of ₹1.75 per share; auditors issued an unmodified opinion.

Why this matters

Profit growing nearly four times faster than revenue is the headline. India was the driver, with domestic sales more than doubling. A clean audit sign-off and a dividend make this a complete annual package.

What we're watching

  • What specifically drove the faster profit growth: pricing, mix, or lower costs.
  • Whether rest-of-world demand at ₹190.94 cr is sustainable after a 78% jump.
  • Management commentary on capacity plans or input costs.

The full read

NGL Fine-Chem reported a 128% jump in consolidated net profit to ₹48.13 crore for FY26, on a 36% rise in revenue to ₹500.95 crore. The profit line grew nearly four times faster than the top line. India was the standout, with domestic revenue more than doubling to ₹157.90 crore. Rest-of-world sales also surged 78% to ₹190.94 crore. The board proposed a ₹1.75 per share final dividend, and the auditors signed off cleanly. The filing itself is a routine annual results disclosure, but the numbers are not routine. A 128% profit increase on a 36% revenue gain is the kind of result that makes you look twice at the cost structure.

Questions answered

How did the different geographies perform?
India revenue more than doubled to ₹157.90 crore, Asia Pacific rose 28% to ₹144.45 crore, and rest-of-world jumped 78% to ₹190.94 crore. Domestic growth was the fastest.
What does the gap between revenue and profit growth indicate?
Net profit grew 128% on 36% revenue growth. That gap points to either better pricing, a shift to higher-margin products, or lower costs. The filing doesn't specify which.
Were there any audit concerns?
No. The auditors gave an unmodified opinion on the consolidated results, meaning no qualifications or emphasis-of-matter paragraphs.
What is the proposed dividend?
The board recommended a final dividend of ₹1.75 per share for the year.
Mentioned: ₹500.95 cr revenue · ₹48.13 cr net profit · ₹1.75 dividend per share
Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Company snapshot

NGL Fine-Chem Ltd.

Pharmaceuticals
₹1,668 cr
P/E 34.67×

Latest quarter · Mar 2026

Sales₹149 cr
Net profit₹13 cr
Op. margin+14.3%
EPS₹21.83

Strength & growth

Debt / equity0.27×
Current ratio1.98×
Sales CAGR+17.9%
EPS CAGR+15.1%
  1. 22 May 2026 · 10:54 AM IST NGL Fine-Chem profit jumps 128% as India revenue more than doubles
  2. 51d ago NGL Fine-Chem profit more than doubles to ₹48 cr on broad-based demand
  3. 52d ago NGL Fine-Chem profit jumps 128% on strong domestic and export demand
  4. 52d ago NGL Fine-Chem profit surges 128% on broad geographic growth
  5. 52d ago NGL Fine-Chem profit surges 128% as Indian revenue doubles